ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Amneal Pharmaceuticals Holding Co

Amneal Pharmaceuticals Holding Co (AMRX)

5.87
0.00
(0.00%)
Closed April 19 4:00PM
0.00
0.00
(0.00%)

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
5.87
Bid
-
Ask
-
Volume
-
0.00 Day's Range 0.00
1.575 52 Week Range 5.95
Market Cap
Previous Close
5.87
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
307,006,908
Dividend Yield
-
PE Ratio
-21.45
Earnings Per Share (EPS)
-0.27
Revenue
2.41B
Net Profit
-83.99M

About Amneal Pharmaceuticals Holding Co

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inha... Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Amneal Pharmaceuticals Holding Co is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker AMRX. The last closing price for Amneal Pharmaceuticals was $5.87. Over the last year, Amneal Pharmaceuticals shares have traded in a share price range of $ 1.575 to $ 5.95.

Amneal Pharmaceuticals currently has 307,006,908 shares outstanding. The market capitalization of Amneal Pharmaceuticals is $1.80 billion. Amneal Pharmaceuticals has a price to earnings ratio (PE ratio) of -21.45.

AMRX Latest News

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or...

Amneal to Report First Quarter 2024 Results on May 3, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open. The Company will...

Amneal to Ring the Nasdaq Closing Bell on April 2, 2024

- Celebrating Amneal’s recent listing on the Nasdaq Stock Exchange Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, today announced that...

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

- Product references branded Ciprodex - Represents another complex, high value new product Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced it has received...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
262.2763.05555555563.65.953.3613517224.52007288CS
524.26264.5962732921.615.951.57511872893.68826072CS
156-0.03-0.5084745762715.96.211.249977873.62215971CS
260-6.99-54.354587869412.8614.31.2413396694.16454741CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TWGTop Wealth Group Holding Ltd
$ 3.73
(101.62%)
36.52M
CSLRComplete Solaria Inc
$ 0.465319
(75.59%)
16.64M
SHOTWSafety Shot Inc
$ 0.48
(60.00%)
6.71k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
MNDRMobile health Network Solutions
$ 27.2386
(33.72%)
10.35M
YYAIConnexa Sports Technologies Inc
$ 0.8943
(-57.21%)
13.4M
SBFMSunshine Biopharma Inc
$ 1.77
(-46.69%)
11.9M
GTIGraphjet Technology
$ 6.43
(-33.09%)
95.33k
ISPCiSpecimen Inc
$ 0.2883
(-31.52%)
2.86M
BGLCBioNexus Gene Lab Corporation
$ 0.5998
(-29.32%)
735.88k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
SQQQProShares UltraPro Short QQQ
$ 12.84
(6.38%)
219.91M
AGBAAGBA Group Holding Ltd
$ 1.255
(21.84%)
128.79M
TQQQProShares UltraPro QQQ
$ 49.48
(-6.20%)
125.4M
SINTSiNtx Technologies Inc
$ 0.0414
(3.50%)
109.94M

AMRX Discussion

View Posts
Monksdream Monksdream 3 weeks ago
AMRX under $10
👍️0
Luckypennyman Luckypennyman 1 year ago
Amarin Announces New REDUCE-IT® Data. March 5, 2023.

DUBLIN, Ireland and BRIDGEWATER, N.J., March 05, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a new analysis from the VASCEPA/VAZKEPA (icosapent ethyl) cardiovascular outcomes REDUCE-IT study showing the effectiveness of VASCEPA®/VAZKEPA® in patients with recent acute coronary syndrome (<12 months before randomization). This post-hoc analysis showed that icosapent ethyl (IPE) substantially and significantly reduced the risk of first and total ischemic events by 37% and 36% respectively in patients with recent acute coronary syndrome (ACS) without increasing bleeding, supporting early initiation of IPE after ACS. The data were presented at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Heart Federation’s World Congress of Cardiology in New Orleans, LA.

https://healthstockshub.com/news/nasdaq/amrn/amarin-announces-new-reduce-it-data-at-acc-23-wcc-showing-benefit-of-vascepa-vazkepa-icosapent-ethyl-in-high-risk-patients-with-a-recent-acute-coronary-syndrome-event
👍️0
Jake L Jake L 3 years ago
AMRX - Update

👍️0
TrendTrade2016 TrendTrade2016 3 years ago
monster bio beast ready to beast in beast land!!
👍️0
ClayTrader ClayTrader 3 years ago
* * $AMRX Video Chart 03-08-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
ListenToMe ListenToMe 3 years ago
AMRX is a good long term hold.
👍️0
ListenToMe ListenToMe 3 years ago
I was hoping AMRX would have better news
👍️0
ListenToMe ListenToMe 3 years ago
Any opinions on AMRX for 2021?
👍️0
ListenToMe ListenToMe 3 years ago
AMRX... the time will come.!
👍️0
ListenToMe ListenToMe 3 years ago
Looks like amrx is going into the 3's
👍️0
ListenToMe ListenToMe 3 years ago
I agree AMRX needs a good catalyst to bring some well deserved attention to this company!

AMRX has huge potential!!
👍️0
Elpapibh Elpapibh 3 years ago
It’s a fantastic play, it’s just they’re in the background and no demand for shares can keep this where it’s at
👍️0
ListenToMe ListenToMe 3 years ago
I'm still thinking AMRX will be a great Sleeper play!!
👍️0
ListenToMe ListenToMe 3 years ago
AMRX is getting a little bounce today. nice
👍️0
Elpapibh Elpapibh 3 years ago
No demand, yet
👍️0
ListenToMe ListenToMe 3 years ago
I'm really surprised this thing isn't 4X Higher.

AMRX
👍️0
Elpapibh Elpapibh 3 years ago
Close to 2 bil market cap no reason for such a dip. Let’s see how the re-recovery looks.
👍️0
Elpapibh Elpapibh 3 years ago
Let’s see what these earnings dooo
👍️0
Elpapibh Elpapibh 3 years ago
Another snack of a close.!! Who’s riding this wave with me???
👍️0
Elpapibh Elpapibh 3 years ago
Fantastic close...
👍️0
Elpapibh Elpapibh 3 years ago
Did I jump on the train too late? I think not. Why isn’t this company forum more popping?
👍️0
ListenToMe ListenToMe 4 years ago
AMRX could be a doubler by end of year!
👍️0
ListenToMe ListenToMe 4 years ago
Amneal is a solid company and will pay off big.
👍️0
Bngo Bngo 4 years ago
With President Trump trying to bring API manufacturing back to The USA to help us rely less on China and India, hopefully all US drug manufacturers can all benefit from this move including Amneal.

Here is a good reason why Amneal is a great candidate for long term success.

https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-to-Acquire-Majority-Interest-in-AvKARE-Enhancing-Access-to-Growing-Federal-Healthcare-Market/default.aspx
👍️0
dangerx dangerx 4 years ago
Nice week AMRX ??
👍️0
dangerx dangerx 4 years ago
Shorts and scares. Plus the whole generic pharmaceutical market has been in the crapper for years. Amneal has done great things during that time like launching high value generics and acquiring valuable manufacturers and distributors. It’s only a matter of time before their NDAs and bioequivalents start being major profit centers. Glad you’re on board with this little pharmaceutical company that could (and has!)
👍️0
ListenToMe ListenToMe 4 years ago
I agree AMRX is a big Winner!!
👍️0
Bngo Bngo 4 years ago
This should be a good reason why Amneal is a great candidate for long term success.


https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-to-Acquire-Majority-Interest-in-AvKARE-Enhancing-Access-to-Growing-Federal-Healthcare-Market/default.aspx
👍️0
Bngo Bngo 4 years ago
I like the company with its promising government contract, but why are we still so far away from $182?
👍️0
ListenToMe ListenToMe 4 years ago
AMRX is my fav. Pharma play.
👍️0
ListenToMe ListenToMe 4 years ago
AMRX ... buy the dip.
Very solid company.
👍️0
ListenToMe ListenToMe 4 years ago
AMRX is a GREAT long-term play.
Many drugs in the pipeline, sales have been consistently increasing and its a US manufacturer.

WIN WIN WIN


AMRX
👍️0
ListenToMe ListenToMe 4 years ago
AMRX has huge potential. Positioned perfectly to capitalize on the rebirth of US drugs!
👍️0
dangerx dangerx 4 years ago
I think institutional investors might come to play too. I’m pretty sure it was over 90% last year and now 69% according to schwab. If that number grows I’ll have 0 worries here.
👍️0
ListenToMe ListenToMe 4 years ago
#FACT...$182 was the price target last year for AMRX. From at least TWO (2) major analysts.


AMRX = Big $$$$

👍️0
ListenToMe ListenToMe 4 years ago
As I was saying... AMRX is quietly laying the groundwork for significant developments!$$$


AMRX = Extremely Strong BUY$$$$....



BOOM
👍️0
ListenToMe ListenToMe 4 years ago
AMRX is just cruising along and laying low right now...BUT the day of recognition is coming!!$$

And it will be one of the Most talked about companies in the world ??!$$$

AMRX
👍️0
ListenToMe ListenToMe 4 years ago
Now you're talking!!
I like the sound of that.

AMRX is Awesome!!!
👍️0
dangerx dangerx 4 years ago
Shorts cover, approval for biosimilar meds, or Kodak’s grant gets cancelled and goes to AMRX instead.

I’d be happy with a short squeeze.
👍️0
ListenToMe ListenToMe 4 years ago
So I'm trying to figure out what would be a great catalyst to make AMRX surge to the next level above $20.00 range.

Hmmmmm
👍️0
ListenToMe ListenToMe 4 years ago
Lots of interest in AMRX.
👍️0
dangerx dangerx 4 years ago
Things haven’t even got going yet... This is just the tap water in the pot when you first turn on the burner.
👍️0
ListenToMe ListenToMe 4 years ago
And.... HERE WE GO!!$$$

amrx
👍️0
ListenToMe ListenToMe 4 years ago
Looking Very Strong!!

AMRX
👍️0
ListenToMe ListenToMe 4 years ago
Can't go wrong with AMRX!!!
👍️0
ListenToMe ListenToMe 4 years ago
Can't go wrong with AMRX!!!
👍️0
ListenToMe ListenToMe 4 years ago
AMRX... $5.00 - $10.00 - $50.00 - $100+ !!!$$$$
👍️0
ListenToMe ListenToMe 4 years ago
$182 was the price target last year for AMRX. From TWO major analysts.
👍️0
ListenToMe ListenToMe 4 years ago
Insiders are loading AMRX.

Value buyers are buying.

AMRX IS the Most undervalued pharma stock .
👍️0
ClayTrader ClayTrader 4 years ago
Thanks for the feedback.
👍️0

Your Recent History

Delayed Upgrade Clock